‘Pharma Bro’ Martin Shkreli is in trouble with regulators again, this time for influencing biopharma stocks
Merck To Present First-Time Results From Three Pivotal Clinical Trials At ESMO Congress; Data Demonstrate Improvements In Recurrence-Free Survival And Distant Metastasis-Free Survival Versus KEYTRUDA Alone In Patients With Completely Resected Stage...